Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.57 |
| ▸ | TLR8 | Q9NR97 | 2/20 | 0.42 |
| ▸ | TLR7 | Q9NYK1 | 2/20 | 0.42 |
| ▸ | TLR9 | Q9NR96 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | CCR2 | P41597 | 1/20 | 0.41 |
| ▸ | PRCP | P42785 | 1/20 | 0.41 |
| ▸ | CTSC | P53634 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24681331 | 0.92 | SLC18A3 (0.49) | SLC18A3TLR8TLR7TLR9DRD2 | |
| SCHEMBL22804565 | 0.87 | SLC18A3 (0.55) | SLC18A3TLR8TLR7TLR9DRD2 | |
| SCHEMBL24494955 | 0.87 | SLC18A3 (0.55) | SLC18A3TLR8TLR7TLR9DRD2 | |
| SCHEMBL6247690 | 0.83 | SLC18A3 (0.57) | SLC18A3TLR8TLR7TLR9DRD2 | |
| SCHEMBL17630951 | 0.83 | SLC18A3 (0.48) | SLC18A3TLR8TLR7TLR9DRD2 | |
| SCHEMBL16994792 | 0.83 | SLC18A3 (0.51) | SLC18A3TLR8TLR7TLR9DRD2 | |
| SCHEMBL22805198 | 0.81 | SLC18A3 (0.62) | SLC18A3TLR8TLR7TLR9DRD2 | |
| SCHEMBL22805197 | 0.81 | SLC18A3 (0.62) | SLC18A3TLR8TLR7TLR9DRD2 | |
| SCHEMBL17306126 | 0.81 | SLC18A3 (0.49) | SLC18A3TLR8TLR7TLR9DRD2 | |
| SCHEMBL4519074 | 0.81 | SLC18A3 (0.52) | SLC18A3TLR8TLR7TLR9DRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2024-10-17 | — | — | US | disclosed |
| WO-2022226668-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | CMPK1, WNK1, AAK1 | SLC18A3 3066/4885TLR8 4558/4885TLR7 3919/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.